Overview

The global AI Diagnostics Market was valued at USD 2.3 billion in 2025 and is projected to reach USD 15.0 billion by 2034, growing at a CAGR of 23.1% during the forecast period (2026-2034). The market is driven by rising diagnostic imaging volumes, persistent radiologist and pathologist workforce shortages, and accelerating adoption of AI-enabled triage, screening, and companion-diagnostic tools across hospitals, diagnostic laboratories, and pharmaceutical research organizations worldwide. The market is shifting from conventional, narrow, single-condition algorithms cleared for one specific finding toward unified, multi-condition foundation models and enterprise AI operating platforms that can be deployed and governed across an entire hospital system from a single interface.  Government initiatives such as the U.S. Food and Drug Administration's Predetermined Change Control Plan guidance, finalized on August 18, 2025 to let manufacturers pre-authorize iterative algorithm updates without a new marketing submission for every change, are easing the regulatory path for AI-enabled diagnostic devices. In the United Kingdom, the National Health Service's AI Diagnostic Fund has provided GBP 21 million to 12 imaging networks covering 64 NHS trusts to accelerate deployment of AI imaging and decision-support tools for cancer, stroke, and cardiac diagnosis. By Country, North America held the largest share of the AI diagnostics market in 2025, supported by the highest concentration of FDA-cleared AI devices, deep venture investment, and early hospital adoption across the United States. Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by expanding healthcare digitization, rising diagnostic imaging volumes, and growing government-backed AI health initiatives across China, India, Japan, and South Korea.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Shift Toward Enterprise AI Operating Platforms and Multi-Condition Foundation Models

• Health systems are moving away from single-condition point solutions toward unified enterprise AI operating platforms capable of managing dozens of diagnostic algorithms from one governance layer. This consolidation reduces integration overhead for hospital IT departments and allows a single vendor relationship to cover triage across CT, X-ray, and cardiology workflows simultaneously.
• Foundation-model architectures trained across acute-care indications are replacing narrow, single-finding algorithms that previously required separate regulatory clearances and separate deployments. Aidoc's CARE foundation model, cleared by the FDA in January 2026 to cover eleven newly authorized indications alongside three prior clearances, illustrates how a single trained model can now support double-digit diagnostic use cases within one workflow.
• Radiology departments, emergency rooms, and increasingly ambulatory imaging centers are adopting these unified platforms because they reduce alert fatigue and standardize how critical findings are escalated to on-call physicians. Multi-hospital health systems are consolidating vendor contracts around platforms that can be centrally monitored and audited across every affiliated site rather than managing dozens of point solutions.
• The U.S. Food and Drug Administration finalized its Predetermined Change Control Plan guidance for AI-enabled device software functions, formally allowing manufacturers to pre-authorize planned algorithm modifications within a single marketing submission. This regulatory shift directly supports the foundation-model trend by letting vendors update multi-condition platforms without filing a new application for every iterative change

KEY MARKET DRIVER

Escalating Radiologist and Pathologist Workforce Shortages Driving Adoption of Diagnostic AI

• Persistent shortages of radiologists and pathologists across the United States, Europe, and parts of Asia are forcing health systems to adopt AI triage tools that prioritize the most urgent studies for immediate physician review. Rising imaging volumes combined with a specialist workforce that is not growing at the same pace are extending report turnaround times, creating direct pressure for automation.
• Diagnostic imaging volumes have grown steadily as populations age and chronic disease screening programs expand, while medical training pipelines for radiology and pathology specialties have not scaled at a comparable rate. This structural mismatch between imaging demand and specialist supply is the most cited justification hospital administrators give when approving AI diagnostic software budgets.
• AI-based triage and prioritization tools directly address this gap by flagging time-critical findings such as large-vessel occlusion stroke, pulmonary embolism, and intracranial hemorrhage within minutes of image acquisition, rather than waiting for sequential worklist review. Hospitals adopting these tools report measurable reductions in door-to-treatment time for stroke and other acute conditions.
• GE HealthCare announced that it had topped the U.S. FDA's list of AI-enabled medical device authorizations for the fourth consecutive year, reaching 100 listed authorizations and targeting more than 200 by 2028. The company directly attributed this sustained investment to rising customer demand for AI tools that improve diagnostic efficiency and address workforce capacity constraints.

KEY MARKET OPPORTUNITY

Expansion of AI-Enabled Companion Diagnostics and Digital Pathology Creating New Revenue Streams

• Pharmaceutical companies are increasingly relying on AI-assisted biomarker analysis to identify eligible patients for precision oncology therapies, creating a new commercial channel for diagnostic AI vendors beyond traditional hospital sales. This shift opens opportunities for AI companies to earn recurring revenue from clinical-trial and companion-diagnostic partnerships rather than one-time software licenses alone.
• Digital pathology foundation models capable of predicting multiple biomarkers from a single tissue slide are reducing the cost and turnaround time of companion-diagnostic testing, making precision oncology accessible to a broader population of patients and smaller laboratories. This creates opportunities for vendors to expand from single-cancer-type products into multi-cancer diagnostic platforms.
• Contract research organizations and reference laboratories are integrating third-party AI platforms into their existing workflows rather than building proprietary models, opening a growing services and licensing opportunity for established digital pathology vendors. This trend is expanding the addressable market beyond hospital pathology departments into the broader clinical-trial and drug-development ecosystem.
• Tempus AI completed its acquisition of digital pathology company Paige for USD 81.25 million, explicitly to grow its companion-diagnostic dataset and expand its oncology foundation-model capabilities. Separately, Lunit entered a strategic collaboration with contract research organization CellCarta in September 2025 to integrate its SCOPE platform into pharmaceutical biomarker and companion-diagnostic workflows.

AI Diagnostics Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Component

The software segment held the largest market share in 2025 because diagnostic algorithms, image-analysis engines, and clinical decision-support platforms form the core value proposition that hospitals purchase and license repeatedly across imaging modalities. Vendors such as Aidoc, Viz.ai, and Qure.ai monetize primarily through software licensing and subscription-based access to FDA-cleared algorithms rather than physical instruments, which keeps software at the center of procurement budgets. Continuous algorithm retraining, cloud-hosted inference, and integration with picture archiving and communication systems further cement software's position, as health systems increasingly consolidate multiple diagnostic use cases onto a single software-defined AI platform rather than acquiring separate hardware for each clinical application.

Services are projected to grow at the fastest CAGR during the forecast period as hospitals move beyond pilot deployments toward enterprise-wide AI governance, requiring implementation, integration, algorithm validation, and continuous performance-monitoring support that software licenses alone do not provide. The Predetermined Change Control Plan framework finalized by the FDA in August 2025 obligates manufacturers and providers to document and monitor iterative algorithm modifications, creating sustained demand for specialized validation and compliance services. As health systems scale from single-use-case pilots to platform-wide deployment across radiology, pathology, and cardiology, demand for consulting, workflow-integration, and managed-service offerings is rising faster than product sales alone.

Component categories include

                       ·           Software (Dominating Segment)

                       ·           Services (Highest CAGR Segment)

                       ·           Hardware

Analysis by Technology

Deep learning held the largest market share in 2025 because convolutional neural network architectures underpin the majority of FDA-cleared imaging algorithms used for stroke, pulmonary, cardiac, and oncology triage. Vendors including Aidoc, Viz.ai, and Lunit train their flagship products on millions of clinically annotated images, giving deep learning models the accuracy and regulatory track record needed for routine clinical adoption. The technology's proven ability to detect subtle patterns across CT, MRI, X-ray, and digital pathology slides that are difficult for rule-based systems to capture has made it the default architecture for new product development across nearly every diagnostic imaging application.

Natural language processing is projected to grow at the fastest CAGR during the forecast period as diagnostic AI expands beyond image interpretation into automated report drafting, structured data extraction from unstructured clinical notes, and voice-enabled documentation. Aidoc's First Read application, which received FDA Breakthrough Device Designation in June 2026 for generating preliminary chest X-ray report drafts, illustrates how natural language processing is being layered onto existing imaging platforms to reduce radiologist documentation burden. As health systems face persistent radiologist and pathologist shortages, reporting tools that compress the time between image acquisition and finalized clinical documentation are attracting rapid vendor investment.

Technology categories include

                       ·           Deep Learning (Dominating Segment)

                       ·           Natural Language Processing (Highest CAGR Segment)

                       ·           Machine Learning

                       ·           Computer Vision

                       ·           Others

Analysis by Application

Radiology held the largest market share in 2025 because imaging accounts for the majority of FDA-authorized AI-enabled device clearances, with more than 1,400 such devices authorized by the end of 2025 and radiology representing roughly three-quarters of all clearances. High imaging volumes, radiologist workforce shortages, and mature reimbursement pathways for CT and X-ray triage tools have made radiology the most commercially proven diagnostic application. Established platforms from Aidoc, Viz.ai, and GE HealthCare that flag strokes, pulmonary embolism, and intracranial hemorrhage across thousands of hospitals demonstrate radiology's central, revenue-generating role within the broader AI diagnostics ecosystem.

Pathology is projected to grow at the fastest CAGR during the forecast period as whole-slide imaging adoption accelerates and AI models move from single-biomarker detection toward foundation models capable of predicting dozens of biomarkers from a single tissue slide. Tempus AI's acquisition of Paige in August 2025 for USD 81.25 million, adding a dataset of nearly seven million digitized pathology slides, exemplifies the scale of investment now flowing into pathology-focused AI. As companion-diagnostic and biomarker-driven oncology treatment decisions expand, pathology laboratories are adopting AI at a pace that outstrips growth in more mature imaging applications.

Application categories include

                       ·           Radiology (Dominating Segment)

                       ·           Pathology (Highest CAGR Segment)

                       ·           Cardiology

                       ·           Neurology

                       ·           Oncology

                       ·           Others

Analysis by Deployment Mode

On-premise deployment held the largest market share in 2025 because large hospital systems and academic medical centers continue to favor locally hosted infrastructure for diagnostic imaging AI to meet strict patient-data residency, cybersecurity, and picture archiving system integration requirements. Enterprise AI operating platforms such as Aidoc's aiOS are frequently deployed within a hospital's own data center to allow direct connectivity with existing radiology and electronic medical record workflows without transmitting protected health information off-site. Regulatory sensitivity around diagnostic data, combined with the sunk investment many providers have already made in on-site imaging infrastructure, continues to support on-premise deployment as the default choice for high-volume diagnostic environments.

Cloud-based deployment is projected to grow at the fastest CAGR during the forecast period as vendors increasingly offer diagnostic AI through software-as-a-service models that lower upfront infrastructure costs for smaller hospitals, diagnostic laboratories, and ambulatory imaging centers. Lunit's 2025 collaboration with Microsoft to build enterprise-ready cloud offerings and Qure.ai's global deployment across more than ninety countries illustrate how cloud infrastructure is enabling diagnostic AI to reach facilities that lack the capital or IT staff to support on-premise systems. Growing comfort with cloud-hosted protected health information, supported by improved encryption and compliance certifications, is accelerating this shift industry-wide.

Deployment Mode categories include

                       ·           On-Premise (Dominating Segment)

                       ·           Cloud-Based (Highest CAGR Segment)

                       ·           Hybrid

Analysis by End User

Hospitals held the largest market share in 2025 because the majority of FDA-cleared diagnostic AI tools are designed for integration into hospital radiology, emergency, and cardiology departments where imaging volumes and clinical urgency are highest. GE HealthCare's achievement of more than 100 FDA AI-enabled device authorizations by mid-2025, the highest of any single manufacturer, reflects how concentrated diagnostic AI adoption remains within large hospital and health-system environments. The scale of capital investment, existing imaging infrastructure, and direct access to specialists needed to validate AI-flagged findings keep hospitals and diagnostic centers at the center of commercial deployment.

Diagnostic laboratories are projected to grow at the fastest CAGR during the forecast period as AI-enabled digital pathology and companion-diagnostic testing expand beyond hospital-based anatomic pathology into independent and reference laboratory networks. Lunit's September 2025 collaboration with contract research organization CellCarta to integrate its SCOPE platform into biomarker-strategy and companion-diagnostic workflows demonstrates how laboratory-based AI adoption is accelerating as pharmaceutical partners seek faster, AI-assisted biomarker readouts for clinical trials. As precision oncology testing volumes rise and reimbursement for AI-assisted laboratory analysis improves, independent diagnostic laboratories are adopting AI tools at a faster pace than the broader hospital-dominated market.

End User categories include

                       ·           Hospitals (Dominating Segment)

                       ·           Diagnostic Laboratories (Highest CAGR Segment)

                       ·           Ambulatory Care Centers

                       ·           Academic and Research Institutes

                       ·           Others

By Region

AI Diagnostics Market Regional Analysis

AI Diagnostics Market Share 2025, (CAGR)

North America

44%

South America

XX%

Europe

XX%

Middle East Africa

XX%

Asia Pacific

24%

Regional Analysis

North America held the largest share of the AI diagnostics market in 2025, accounting for approximately 44% of global revenue, supported by the United States' position as the largest single market for FDA-cleared AI-enabled medical devices, with more than 1,400 such devices authorized by the end of 2025 and radiology representing roughly three-quarters of all clearances. Deep venture capital investment, exemplified by Aidoc's USD 110 million funding round in July 2025 and Tempus AI's USD 81.25 million acquisition of Paige in August 2025, continues to concentrate capital and innovation within the region. Established health systems across the United States and Canada have integrated AI triage platforms from vendors such as Aidoc, Viz.ai, and GE HealthCare into routine stroke, pulmonary, and cardiac care, while the FDA's 2025 Predetermined Change Control Plan guidance is streamlining ongoing algorithm updates across the region's large installed base of AI-enabled devices.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by rapid healthcare digitization, rising diagnostic imaging volumes, and expanding government-backed AI health programs across China, India, Japan, and South Korea. India-headquartered Qure.ai has deployed AI-powered chest X-ray, tuberculosis, and stroke-triage tools across more than ninety countries and partnered with Johnson & Johnson MedTech in May 2025 to expand early lung cancer detection, while South Korea's Lunit has scaled its breast cancer AI ecosystem to more than 330 healthcare providers across the Americas and continues to secure new international screening contracts through its global expansion strategy. Rising public health screening programs for tuberculosis and lung cancer, combined with growing local adoption of AI-enabled diagnostic software, are positioning Asia-Pacific as the region with the strongest incremental growth in AI diagnostics adoption through 2034.

Countries and Regions Covered

North America (Dominating Region)

o    United States (Largest Country Market)

o    Canada (Fastest-Growing Country Market)

o    Mexico

Asia-Pacific (Fastest Growing Region)

o    China (Largest Country Market)

o    India (Fastest-Growing Country Market)

o    Japan

o    South Korea

o    Rest of Asia-Pacific

Europe

o    Germany (Largest Country Market)

o    United Kingdom (Fastest-Growing Country Market)

o    France

o    Italy

o    Rest of Europe

Latin America

o    Brazil (Largest Country Market)

o    Chile (Fastest-Growing Country Market)

o    Rest of Latin America

Middle East & Africa

o    Saudi Arabia (Largest Country Market)

o    United Arab Emirates (Fastest-Growing Country Market)

o    Rest of Middle East & Africa

Market Share

The AI diagnostics market is fragmented, with a mix of specialized AI-native companies and large diversified medical technology firms competing for share across imaging, pathology, and cardiology applications. Established medical device manufacturers such as GE HealthCare, Siemens Healthineers, and Philips leverage existing hospital relationships and integrated imaging hardware to bundle AI software with new equipment sales, while venture-backed specialists such as Aidoc, Viz.ai, Qure.ai, and Lunit compete primarily on regulatory clearance breadth, clinical validation, and enterprise platform capability. Continued consolidation is evident in Tempus AI's 2025 acquisition of digital pathology company Paige, as larger platforms acquire specialized point solutions to broaden their diagnostic coverage. Strategic partnerships between AI vendors and pharmaceutical companies, cloud providers, and contract research organizations are increasingly shaping competitive positioning across the industry.

Key Players

                       ·           Aidoc (Israel)

                       ·           Viz.ai, Inc. (US)

                       ·           Tempus AI, Inc. (US)

                       ·           Lunit Inc. (South Korea)

                       ·           Qure.ai (India)

                       ·           Ibex Medical Analytics (Israel)

                       ·           Cleerly, Inc. (US)

                       ·           HeartFlow, Inc. (US)

                       ·           Median Technologies (France)

                       ·           Annalise.ai (Australia)

                       ·           Siemens Healthineers AG (Germany)

                       ·           GE HealthCare Technologies Inc. (US)

                       ·           Koninklijke Philips N.V. (Netherlands)

                       ·           Butterfly Network, Inc. (US)

                       ·           PathAI, Inc. (US)

Recent Market Developments

• In September 2024, Qure.ai (India) completed a USD 65 million Series D funding round, including a strategic investment from the Merck Global Health Innovation Fund, to expand its AI-powered chest X-ray and lung cancer detection platform into the United States and other markets.
• In December 2024, GE HealthCare (US) submitted its CleaRecon DL deep-learning technology for FDA 510(k) clearance, bringing AI-based three-dimensional image reconstruction to cone-beam CT imaging used in interventional radiology suites.
• In May 2025, Johnson & Johnson MedTech (US) partnered with Qure.ai (India) to expand access to AI-powered chest X-ray screening aimed at boosting early detection of lung cancer across global health systems.
• In July 2025, Lunit (South Korea) entered a partnership with Microsoft (US) to co-develop enterprise-ready cloud offerings for its AI-based cancer diagnostics platform, expanding cloud-based deployment options for hospital customers.
• In December 2025, Lunit (South Korea) announced a collaboration with Daiichi Sankyo to apply its SCOPE uIHC and SCOPE IO platforms to AI-based biomarker and companion-diagnostic research in oncology.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is AI Diagnostics?

2

What is the CAGR of the AI Diagnostics Market?

3

Which component leads the AI Diagnostics Market?

4

Which application dominates the AI Diagnostics Market?

5

Which technology has the highest market share?

6

What are the latest trends in the AI Diagnostics Market?

7

Who are the end users of AI Diagnostics?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates